Erika Hamilton

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +12

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Luc Dirix, István Takács, Guy Jérusalem et al. · Breast Cancer Research and Treatment · 2017 · 756 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung et al. · The Lancet · 2022 · 642 citations · Full text

Medicine, Oncology, Pharmacology +16

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin, Virginia F. Borges, Carey K. Anders et al. · Journal of Clinical Oncology · 2020 · 549 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

Mary L. Disis, Matthew H. Taylor, Karen Kelly et al. · JAMA Oncology · 2019 · 427 citations · Full text

Medicine, Oncology, Pharmacology +15